The UK and US have finalized a landmark commercial pact that will keep no tariffs on UK medicine exports entering the US market.
The Terms of the Accord
As part of the deal, the UK has agreed to boost funding on drugs through the NHS. This commitment ensures that duties on these key exports will stay at nothing for a timeframe of three years.
This development follows recent warnings to significantly raise duties on patented pharmaceutical products, with figures discussed up to one hundred percent.
"This arrangement with the United Kingdom bolsters the global environment for new treatments and establishes much-needed fairness to U.S.–U.K. medicine commerce," an announcement said.
Commercial Importance
Pharmaceuticals are one of the Britain's biggest exports to the US, which is by far the primary market for large UK drugmakers.
Statistics indicate that in the 12 months leading up to the third quarter, the UK exported pharmaceutical products worth £11.1bn to the US. This amount made up 17.4% of all goods exports in that period.
"This guarantee secures jobs, increases investment and sets the stage for the UK to become a international leader for medical research," the Business and Trade Secretary commented.
Specific NHS Changes
The pact includes several notable commitments from the United Kingdom:
- Revised Affordability Limit: The UK will raise the cost ceiling at which it considers new treatments to be too expensive by 25%.
- Higher Drug Budget: There is a aim to raise overall public funding on medicines from 0.3% of Gross Domestic Product to 0.6 percent over the following ten-year period.
- Rebate Cap: The amount drug companies must return to the NHS to prevent overspending will be limited at 15%. Previously, repayments topped 20%.
Industry Background
The pact takes place against a protracted tension between the pharmaceutical industry and the ministers over spending levels and approval rates.
The disagreement were exacerbated by arguments that US patients were paying several times more for the same drugs than patients in the UK and Europe.
In recent months, several major pharmaceutical investments in the UK have been halted or scrapped, while major funding commitments have been pledged toward American operations.
One official publicly accepted that the NHS must spend more on drugs, noting that its spending on drugs had shrunk as a percentage of its overall budget over the last ten years.
